![]() |
|
| Systematic (IUPAC) name | |
|---|---|
| methyl 6-({[(2-chloroethyl)(nitroso)amino]carbonyl}amino)-6-deoxy-α- D-glucopyranoside | |
| Identifiers | |
| CAS number | 58994-96-0 |
| ATC code | L01AD07 |
| PubChem | 71741 |
| Chemical data | |
| Formula | C 10H18ClN3O7 |
| Mol. mass | 327.71 g/mol |
| SMILES | eMolecules & PubChem |
| Synonyms | 1-(2-chloroethyl)-1-nitroso-3-([(2R,3S,4 S,5R,6S)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl)urea |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. | ? |
| Legal status | ℞ Prescription only |
| Routes | IV |
Ranimustine (INN, marketed under the tradename Cymerin; also known as MCNU) is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia[1] and polycythemia vera.[2]
It has never been filed for FDA evaluation in the United States, where it is not marketed.
|
|